TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01310205

Intervention type: DRUG
Intervention: SCV-07
Description: This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV

Intervention type: DRUG
Intervention: SCV-07
Description: This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
Study: NCT01675544

Intervention type: PROCEDURE
Intervention: Electrocardiogram
Description: EKG voltage changes between admission and discharge

Intervention type: PROCEDURE
Intervention: Six minute walk test
Study: NCT02817932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study: NCT02482818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Increasing dose regimen depending on tolerability followed by decreasing dose regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control-Placebo
Description: A control substance, Lactose is administered in place of Pregabalin.
Study: NCT02746224

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initially dissection of inferior mesenteric vein
Description: Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initially dissection of inferior mesenteric vein
Description: Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initially dissection of inferior mesenteric artery
Description: Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initially dissection of inferior mesenteric artery
Description: Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Latero-terminal colorectal anastomosis
Description: The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Termino-terminal colorectal anastomosis
Description: The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
Study: NCT00904033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol tablet taken once per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol tablet taken once per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise consisting of progressive walking and resistance band training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise consisting of progressive walking and resistance band training

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Study: NCT03398499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIOFOR (Med & Life)
Description: Device: VIOFOR (Med \& Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
Study: NCT04901780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic posterior capsular stretch
Description: pragmatic posterior stretch is used to increase the length of the posterior capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross body stretch
Description: crossbody stretch performed by an individual
Study: NCT03226197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester drink
Description: Ketone ester drink
Study: NCT02834793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo in Randomization phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perampanel
Description: Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
Study: NCT01320137

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood withdrawal
Description: Blood sampling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood withdrawal
Description: Blood sampling
Study: NCT02089893

Intervention type: DEVICE
Intervention: Fundus photography
Description: Non-mydriatic fundus photographs
Study: NCT02049541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamics
Description: Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
Study: NCT01874340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at predefined visits over the 6-month treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 will be administered at predefined visits over the 6-month treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 will be administered at predefined visits over the 6-month treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 will be administered at predefined visits over the 6-month treatment phase.
Study: NCT02506803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC-GEMABR
Description: NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
Study: NCT00555061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin Ointment, 1%
Description: 1% Ointment
Study: NCT01358721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Anti-PD-1)
Description: Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
Study: NCT06273696

Intervention type: DEVICE
Intervention: ShangRing
Description: The ShangRing is a sterile, single use, disposable male circumcision (MC) device that consists of two concentric plastic rings, the inner of which is lined by a silicone pad, which provides a smooth and non-bio reactive surface against the surgical wound. The outer ring consists of 2 halves which are hinged together at the same end. On each side of the halves there is a locking clasp which allows for locking itself with inner ring. The ShangRing device is removed seven days after placement.
Study: NCT02505828

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Articular punction, salivary samples, blood sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Articular punction, salivary samples, blood sample
Study: NCT01145677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 100-300 mg/day orally twice per day
Study: NCT04259918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
Study: NCT01334619

Intervention type: PROCEDURE
Group type: OTHER
Intervention: appropriate volume of 0.5% ropivacaine
Description: initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
Study: NCT00970684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg on day 1 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 900 mg/m2 on days 1, and 8,
Study: NCT02616588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Patient Navigator and Social Work Intervention
Description: Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
Study: NCT02088138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation placebo
Description: Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
Study: NCT05114642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skeletal Class III Malocclusion Treatment with Face Mask Group
Description: Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
Study: NCT02056262

Intervention type: OTHER
Intervention: Dental cavity evaluation
Description: The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
Study: NCT01770132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Description: Given IV
Study: NCT02056262

Intervention type: OTHER
Intervention: Dental cavity evaluation
Description: The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).

Intervention type: BIOLOGICAL
Intervention: Saliva sampling
Description: A saliva sample will be harvested.

Intervention type: BIOLOGICAL
Intervention: Saliva sampling
Description: A saliva sample will be harvested.

Intervention type: BIOLOGICAL
Intervention: Plaque sampling
Description: Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.

Intervention type: BIOLOGICAL
Intervention: Plaque sampling
Description: Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
Study: NCT00084136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 400 mg taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine (enteric-coated)
Description: 400 mg taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg/300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150 mg/300 mg taken orally twice daily
Study: NCT03189238

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peri-urethral and clitoral injections
Description: Peri-urethral and clitoral injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peri-urethral and clitoral injections
Description: Peri-urethral and clitoral injections
Study: NCT03476590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine
Description: The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations.
Study: NCT00093379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (XRT)
Description: Undergo radiotherapy\* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. \*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
Study: NCT03897517

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Botanical Blend
Description: Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
Study: NCT00888186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: intestinal gel, for continuous daytime infusion
Study: NCT03835832

Intervention type: OTHER
Intervention: The participants do not receive any intervention for this study
Description: The participants do not receive any intervention for this study
Study: NCT04156633

Intervention type: DIAGNOSTIC_TEST
Intervention: conventional identification method: biochemical profiling or MALDI-TOF MS
Description: Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)

Intervention type: DIAGNOSTIC_TEST
Intervention: new identification method: Biofire FilmArray© BCID panel
Description: The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)

Intervention type: DIAGNOSTIC_TEST
Intervention: new identification method: metagenomic WGS
Description: shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
Study: NCT04466202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music with Structured Verbal Training
Description: Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
Study: NCT02155478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ISERT 250 (HOYA, Japan): a standard IOL

Intervention type: DEVICE
Group type: OTHER
Intervention: AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
Study: NCT01770132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasonography
Description: Undergo EUS-PDT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo EUS-PDT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT04434391

Intervention type: OTHER
Intervention: QF-PCR for GBS screening
Description: QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
Study: NCT03828591

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intensive psychological support
Description: Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard psychological support
Description: Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard psychological support
Description: Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
Study: NCT04319107

Intervention type: OTHER
Intervention: ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.
Description: Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.

Intervention type: OTHER
Intervention: ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.
Description: Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
Study: NCT03377907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine in hematoma block
Description: ketamine used in local hematoma block only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine in local intravenous anesthesia
Description: ketamine will be used with lidocaine in local intravenous anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
Study: NCT00893321

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior Oblique Muscle Recession and Myectomy
Study: NCT01689298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.